Hangzhou’s Attractions Play Big Part In New Pfizer China Investment
This article was originally published in PharmAsia News
The Hangzhou Economic Development Area has become a highly attractive spot for global pharmas to establish an expanded presence in China, as its integrated platforms, high quality talent pool and incentives help develop a powerhouse of high-end manufacturing. Pfizer’s $350m decision to join the industrial cluster for a new biotech center follows on from others including MSD, Lilly and Bayer.
You may also be interested in...
Pfizer threw in the towel for biosimilar development in China last week, just three years after opening its $350m Global Biotechnology Center, based in the Hangzhou Economic Development Area.
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.